Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia

Home Administration Of Nivestim(tm) In The Primary Prophylaxis Of Chemotherapy- Induced Febrile Neutropenia Non-interventional, Observational, Prospective Study Short Name: Home Short Name: Home

Non-interventional, non-comparative, national, multi-site, single-arm prospective observational study to investigate home administration of Nivestim in the primary prophylaxis of chemotherapy-Induced febrile neutropenia

Inclusion Criteria:

• Male and female patients ≥ 18 years
• Declaration of informed consent signed by patient
• Patients with a solid tumour or with a malignant haematological tumour
• Patients who have been prescribed cytotoxic chemotherapy, irrespective of current cycle
• GCSF-naïve patients or patients pre-treated with GCSF who received no GCSF in the last three months before enrolment
• Patients starting primary prophylactic treatment using NivestimTM either to shorten the duration of a neutropenia or to prevent the occurrence of chemotherapy-induced FN

Exclusion Criteria:

• Patients with chronic myeloid leukaemia (CML) or with myelodysplastic syndrome (MDS)
• Patients who are hypersensitive to one of the excipients of NivestimTM
• Patients not undergoing chemotherapy
• Patients being treated curatively or as secondary prophylaxis with G-CSF